Ganne Sudha, Arora Surender K, Dotsenko Olena, McFarlane Samy I, Whaley-Connell Adam
Curr Diab Rep. 2007 Jun;7(3):208-17. doi: 10.1007/s11892-007-0033-3.
Hypertension (HTN) and type 2 diabetes mellitus (T2DM) are emerging as epidemics of the 21st century and are important components of the metabolic syndrome (MS). Evidence demonstrates a relationship between HTN, T2DM, and several vascular and metabolic abnormalities that are components of the MS. HTN affects nearly 70 million Americans and over one billion worldwide; likewise, the MS affects 44% of the US population above the age of 60 years and is rapidly increasing. HTN associated with the MS has certain pathophysiologic characteristics that provide clinical challenges. There is growing evidence that tissue activation of the renin-angiotensin system contributes to endothelial dysfunction, microalbuminuria, insulin resistance, and subsequent increased risk for cardiovascular and chronic kidney disease. The notion that HTN is a metabolic as well as a vascular disease provides a new treatment paradigm.
高血压（HTN）和2型糖尿病（T2DM）正成为21世纪的流行病，并且是代谢综合征（MS）的重要组成部分。有证据表明，HTN、T2DM与作为MS组成部分的几种血管和代谢异常之间存在关联。HTN影响近7000万美国人以及全球超过10亿人；同样，MS影响美国60岁以上人群的44%，且这一比例正在迅速上升。与MS相关的HTN具有某些病理生理特征，带来了临床挑战。越来越多的证据表明，肾素-血管紧张素系统的组织激活会导致内皮功能障碍、微量白蛋白尿、胰岛素抵抗以及随后心血管疾病和慢性肾病风险增加。HTN既是一种代谢性疾病也是一种血管疾病这一观念提供了一种新的治疗模式。
